You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 11, March 15, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  From the Archives Journals: Abstract and Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Osteoporosis
 •Alert me on articles by topic

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy

Commentary by Michael P. Heffernan, MD; Kenneth G. Saag, MD, MSc; June K. Robinson, MD; Jeffrey P. Callen, MD

JAMA. 2006;295(11):1300-1303.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ARCHIVES OF DERMATOLOGY

Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update

Brett T. Summey, MD; Gil Yosipovitch, MD

Objective: To raise awareness of the new treatment options and current recommendations among dermatologists treating patients with systemic corticosteroids.

Data Sources: MEDLINE peer-reviewed publications.

Study Selection: English language and clinical pertinence to corticosteroid-induced osteoporosis.

Data Extraction: Pertinent information on pathophysiologic, epidemiologic, clinical trial, cost-effectiveness, and treatment option data regarding corticosteroid-induced osteoporosis.

Data Synthesis: Comprehensive summary of published data on the pathophysiologic, epidemiologic, clinical, and treatment data and current practice guidelines regarding corticosteroid-induced osteoporosis; creation of an algorithmic management approach for patients treated with long-term oral corticosteroids.

Conclusions: Glucocorticoid-induced bone loss is the most predictable and debilitating complication of prolonged administration of systemic corticosteroids. Every dermatologist prescribing systemic . . . [Full Text of this Article]

Author Affiliations: Division of Dermatology, Wright State University Boonshoft School of Medicine, Dayton, Ohio (Dr Heffernan); Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama, Birmingham (Dr Saag); Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill (Dr Robinson); and Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Ky (Dr Callen). Dr Robinson is the Editor, Archives of Dermatology and Dr Callen is the Associate Editor, Archives of Dermatology.


RELATED ARTICLE

Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Brett T. Summey and Gil Yosipovitch
Arch Dermatol. 2006;142(1):82-90.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.